News

Recent news about Panacea Venture and select portfolio companies

February 12, 2024

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector

February 12, 2024

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector

November 30, 2023

Exciting Update! Explore Myrtelle’s Insightful Slide Presentation on Gene Therapy for Canavan Disease Preliminary One-Year Results from Meeting on the Mesa.

Here is the link to Alliance for Regenerative Medicine's Youtube Channel. Mark Hurtt gave a presentation last month at Mesa, here is the slideshow he presented with…

November 30, 2023

Exciting Update! Explore Myrtelle’s Insightful Slide Presentation on Gene Therapy for Canavan Disease Preliminary One-Year Results from Meeting on the Mesa.

Here is the link to Alliance for Regenerative Medicine's Youtube Channel. Mark Hurtt gave a presentation last month at Mesa, here is the slideshow he presented with…

November 14, 2023

Oxford Nanopore and Day Zero Diagnostics Partner to Develop a New Class of Bloodstream Infection Diagnostics

Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, and Day Zero Diagnostics (DZD)

November 14, 2023

Oxford Nanopore and Day Zero Diagnostics Partner to Develop a New Class of Bloodstream Infection Diagnostics

Oxford Nanopore, the company delivering a new generation of nanopore-based molecular sensing technology, and Day Zero Diagnostics (DZD)

November 6, 2023

Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients

Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…

November 6, 2023

Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients

Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…

November 5, 2023

Poster: SITC 2023 - 38th annual SITC meeting – Nov 1-5 2023, San Diego, CA

PK/PD Biomarker Analysis to Assess Tumor-Specific Enrichment and Payload Delivery of ACTM-838, a Microbial-Based Immunotherapy VIEW POSTER PDF

November 5, 2023

Poster: SITC 2023 - 38th annual SITC meeting – Nov 1-5 2023, San Diego, CA

PK/PD Biomarker Analysis to Assess Tumor-Specific Enrichment and Payload Delivery of ACTM-838, a Microbial-Based Immunotherapy VIEW POSTER PDF